Skip to main content

Leukemia

Vyxeos Now Indicated for Pediatric Patients with AML
Read More
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
Read More
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Read More
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
Read More
Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia
Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day
Read More
Meeting Highlights
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
Read More
Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy
Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP
Read More
Onureg FDA Approved for Adults with AML in Remission
Read More
Retrospective Study of Single Cord Blood Transplantation for Patients with AML Aged ≥60 Years
Read More
Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML
Read More
Page 2 of 7
Results 11 - 20 of 64